Nutex Health, Inc.
For the period ended Sep 30, 2025. Filed Nov 19, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 19, 2025
NUTX$186.25-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited
| Nine Months Ended September 30, | ||
|---|---|---|
| (In thousands) | 2025 | 2024 |
| Cash flows from operating activities: | ||
| Net income | $163,749 | $(4,698) |
| Adjustment to reconcile net income to net cash from operating activities: | ||
| Depreciation and amortization | 15,343 | 13,691 |
| Loss on warrant liability | — | 1,073 |
| Impairment of assets | — | 3,899 |
| Impairment of goodwill | — | 3,197 |
| Derecognition of goodwill | — | 453 |
| Stock-based compensation expense | 119,606 | 1,952 |
| Changes to deferred taxes | 22,942 | (1,743) |
| Debt accretion expense | 756 | 805 |
| Changes in operating assets and liabilities: | ||
| (Increase)/Decrease in Accounts receivable | (154,960) | (4,253) |
| (Increase)/Decrease in Accounts receivable - related party | (3,751) | 550 |
| (Increase)/Decrease in Inventories | (308) | 1,131 |
| (Increase)/Decrease in Income tax receivable | (12,097) | — |
| (Increase)/Decrease in Prepaid expenses and other current assets | (6,376) | (1,361) |
| (Increase)/Decrease in Operating right-of-use assets | 518 | 411 |
| Increase/(Decrease) in Accounts payable | 36,637 | (7,975) |
| Increase/(Decrease) in Accounts payable - related party | 3,276 | (39) |
| Increase/(Decrease) in Operating lease liabilities | (164) | (692) |
| Increase/(Decrease) in Accrued arbitration expenses | 16,571 | — |
| Increase/(Decrease) in Accrued income tax expense | (26,533) | — |
| Increase/(Decrease) in Accrued expenses and other current liabilities | 2,527 | 16,698 |
| Net cash provided by operating activities | 177,736 | 23,099 |
| Cash flows from investing activities: | ||
| Acquisitions of property and equipment | (1,117) | (1,909) |
| Proceeds from restricted short-term investment | 2,941 | — |
| Cash related to sale of business | — | (361) |
| Cash related to asset acquisition | (1,994) | — |
| Net cash used in investing activities | (170) | (2,270) |
| Cash flows from financing activities: | ||
| Proceeds from lines of credit | 5,043 | 1,132 |
| Proceeds from notes payable | 273 | 7,015 |
| Repayments of lines of credit | (3,293) | (1,119) |
| Repayments of notes payable | (8,319) | (8,332) |
| Repayments of finance leases | (4,004) | (1,924) |
| Proceeds from common stock issuance, net issuance costs | — | 9,202 |
| Proceeds from exercise of warrants | — | 801 |
| Members' contributions | 316 | 961 |
| Members' distributions | (42,174) | (3,659) |
| Net cash provided by (used in) financing activities | (52,158) | 4,077 |
| Net increase in cash and cash equivalents | 125,408 | 24,906 |
| Cash and cash equivalents - beginning of the period | 40,640 | 22,002 |
| Cash and cash equivalents - end of the period | $166,048 | $46,908 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.